Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Marvell Technology Inc (MRVL) Price & Performance

Charles River Laboratories Intl. IncTrade
Marvell Technology IncTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Marvell Technology Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B), while Marvell Technology Inc trades at $218.86 (market cap $190.56B). The key difference: Marvell Technology Inc is far larger — about 14.2× Charles River Laboratories Intl. Inc's market cap, and Marvell Technology Inc pays a 0.11% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.

CRLMRVL
Market Cap
$13.46B$190.56B
Sector
HealthTechnology
52-Week High
$282.00$316.43
52-Week Low
$145.57$62.31
Enterprise Value
$16.30B$191.99B
Dividend Yield
0.11%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.

The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.

Marvell Technology Inc

Marvell Technology (MRVL) trades at $221.86, up 6.38% with strong technical momentum and bullish moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and revenue growth to $5.77 billion in 2025. Analyst consensus remains strongly bullish with 82% buy ratings and a $275.68 price target, representing 24% upside potential. Recent news highlights Marvell's positioning in AI infrastructure and optical networking leadership.

Marvell presents significant growth potential driven by AI data center expansion and custom chip programs with Microsoft and NVIDIA. However, investors face risks from premium valuations (P/E 72.96), supply chain constraints, and competitive pressure from Broadcom and AMD. The stock's recent volatility and high beta characteristics require careful risk management despite strong institutional support.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Marvell Technology Inc

Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.

Read more on MRVL